ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CNTA Centessa Pharmaceuticals PLC

16.50
1.40 (9.27%)
14 Sep 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Centessa Pharmaceuticals PLC NASDAQ:CNTA NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  1.40 9.27% 16.50 16.50 17.14 17.59 15.80 17.00 3,258,754 01:00:00

Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

07/06/2021 9:15pm

GlobeNewswire Inc.


Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart


From Sep 2019 to Sep 2024

Click Here for more Centessa Pharmaceuticals Charts.

Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, beginning at 5:30 p.m. Eastern Time.

About Centessa PharmaceuticalsCentessa Pharmaceuticals plc aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations. The asset-centric model refers to a highly specialized, singular-focused company that is led by a team of well-recognized subject matter experts. Centessa wholly owns ten of these asset-centric companies. The companies’ programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Centessa’s asset-centric companies are overseen by the Centessa management team, which sets overall strategy and direction, provides leadership and expertise, and manages resource allocation and shared infrastructure. For more information, visit www.centessa.com.

Contacts:

Investor Contact:Media Contacts:
Jennifer Porcelli, Head of Investor RelationsUS
Centessa PharmaceuticalsDan Budwick, 1AB
jennifer.porcelli@centessa.comdan@1abmedia.com
  
 UK/Greater Europe
 Mary Clark & Shabnam Bashir, Optimum Strategic Communications
 centessa@optimumcomms.com
  
 Switzerland
 Marcus Veith, VEITHing Spirit
 marcus@vspirit.ch
 M: +41 79 20 75 111

1 Year Centessa Pharmaceuticals Chart

1 Year Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock